Alnylam Pharmaceuticals, Inc. (ALNY)

Market Cap	59.14B
Revenue (ttm)	2.46B
Net Income (ttm)	-319.09M
Shares Out	131.08M
EPS (ttm)	-2.46
PE Ratio	n/a
Forward PE	119.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,445,458
Open	455.76
Previous Close	461.24
Day's Range	450.70 - 463.88
52-Week Range	205.87 - 484.21
Beta	0.32
Analysts	Strong Buy
Price Target	435.04 (-3.58%)
Earnings Date	Oct 30, 2025

About ALNY

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 28, 2004
• Employees: 2,230
• Stock Exchange: NASDAQ
• Ticker Symbol: ALNY
• Website: https://www.alnylam.com

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Analyst Summary

According to 29 analysts, the average rating for ALNY stock is "Strong Buy." The 12-month stock price target is $435.04, which is a decrease of -3.58% from the latest price.

Price Target

$435.04

(-3.58% downside)

Analyst Consensus: Strong Buy